Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: None
PBS, pH 7.2
Concentration information loading...
PurityProtein G purified
Light chain typekappa
Our Abpromise guarantee covers the use of ab54576 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 5 µg/ml. Predicted molecular weight: 37 kDa.|
FunctionProbably involved in the control of the cell cycle. Interacts with D-type G1 cyclins.
Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.
Contains 1 protein kinase domain.
- Information by UniProt
- CDK 6 antibody
- CDK6 antibody
- CDK6_HUMAN antibody
Lanes 1, 3 and 5: Wild-type HAP1 cell lysate (20 µg)
Lanes 2, 4 and 6: CDK6 knockout HAP1 cell lysate (20 µg)
Lanes 1 and 2: Green signal from target – ab54576 observed at 37 kDa
Lanes 3 and 4: Red signal from loading control – ab8227 observed at 42 kDa
Lanes 5 and 6: Merged (red and green) signal
ab54576 was shown to react with CDK6 when CDK6 knockout samples were used, along with additional cross-reactive bands. Wild-type and CDK6 knockout samples were subjected to SDS-PAGE. ab54576 and ab8227 (loading control to beta actin) were diluted 1 µg/mL and 1/2000 respectively and incubated overnight at 4ºC. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
Cdk6 antibody (ab54576) at 1ug/lane + Jurkat cell lysate at 25ug/lane.
This product has been referenced in:
- Laurenti E et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16:302-13 (2015). IF . Read more (PubMed: 25704240) »
- von Witzleben A et al. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway. Cancer Res 75:3823-31 (2015). Read more (PubMed: 26183925) »